The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Elevated factor VIII levels and risk of venous thrombosis
Abstract
Summary: Modern thrombophilia testing fails to identify any underlying prothrombotic tendency in a significant number of patients presenting with objectively confirmed venous thromboemboembolism (VTE). This observation has led to a search for other novel inherited or acquired human thrombophilias. Although a number of putative mechanisms have been described, the evidence behind many of these candidates remains weak. In contrast, an increasing body of work supports the hypothesis that increased plasma factor VIII (FVIII) levels may be important in this context. An association between elevated plasma FVIII levels and VTE was first described in the Leiden Thrombophilia Study (LETS). Subsequently, these conclusions have been supported by an increasing number of independent case–control studies. Cumulatively, these studies have clearly demonstrated that high FVIII levels constitute a prevalent, dose‐dependent risk factor for VTE. Furthermore, more recent studies have shown that the risk of recurrent venous thrombosis is also significantly increased in patients with high FVIII levels. In this review, we present the evidence supporting the hypothesis that elevated FVIII levels constitute a clinically important thrombophilia. In addition, we examine the biological mechanisms that may underlie persistently elevated FVIII levels, and the pathways through which high FVIII may serve to increase thrombotic risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079
The Wellcome Trust Case Control Consortium, U.K.
Mossman, K. (2008) · Scientific American · doi:10.1038/scientificamerican0108-42a · Cited by 2,684
Koster, T., Vandenbroucke, J. P., Rosendaal, F. R., Briët, E., Rosendaal, F. R., & Blann, A. D. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90166-3 · Cited by 1,131
The effect of ABO blood group on the diagnosis of von Willebrand disease
Gill, J., Endres-Brooks, J., Bauer, P., Marks, W. J., & Montgomery, R. (1987) · Blood · doi:10.1182/blood.v69.6.1691.1691 · Cited by 957
High plasma levels of factor VIII and the risk of recurrent venous thromboembolism
Kyrle, P. A., Minar, E., Hirschl, M., Bialonczyk, C., Stain, M., Schneider, B., Weltermann, A., Speiser, W., Lechner, K., & Eichinger, S. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430702 · Cited by 763 · cited 3×
“The hypothesis that high plasma FVIII:C levels influence risk of recurrent VTE was further addressed in the larger prospective Austrian Study on Recurrent VTE (Kyrle et al, 2000).”
BackgroundResultHigh Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis
Meijers, J. C. M., Tekelenburg, W. L. H., Bouma, B. N., Bertina, R. M., & Rosendaal, F. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003093421004 · Cited by 700
Clinical guidelines for testing for heritable thrombophilia
Baglin, T., Gray, E., Greaves, M., Hunt, B. J., Keeling, D., Machin, S., Mackie, I., Makris, M., Nokes, T., Perry, D., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08022.x · Cited by 499
High Plasma Concentration of Factor VIIIc Is a Major Risk Factor for Venous Thromboembolism
in 't Anker, P., Koopman, M., Reitsma, P., Prins, M., van den Ende, A., Büller, H., & Kraaijenhagen, R. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613747 · Cited by 489
Conlan, M. G., Folsom, A. R., Finch, A., Davis, C. E., Sorlie, P., Marcucci, G., Wu, K. K., & For the ARIC Study Investigators (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649589 · Cited by 439
ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?
Jenkins, P. V., & O’Donnell, J. S. (2006) · Transfusion · doi:10.1111/j.1537-2995.2006.00975.x · Cited by 431
Self-citation
Cited by
Persistent endotheliopathy in the pathogenesis of long COVID syndrome
Fogarty, H., Townsend, L., Morrin, H., Ahmad, A., Comerford, C., Karampini, E., Englert, H., Byrne, M., Bergin, C., O’Sullivan, J. M., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15490 · Cited by 337
Self-citationThe physiological functions of iron regulatory proteins in iron homeostasis - an update
Zhang, D.-L., Ghosh, M. C., & Rouault, T. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00124 · Cited by 301
Rietveld, I. M., Lijfering, W. M., le Cessie, S., Bos, M. H. A., Rosendaal, F. R., Reitsma, P. H., & Cannegieter, S. C. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14343 · Cited by 154
Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles
Chen, C.-Y., Tran, D. M., Cavedon, A., Cai, X., Rajendran, R., Lyle, M. J., Martini, P. G. V., & Miao, C. H. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.03.015 · Cited by 89
Metadata
- Authors
- Jenkins, P. V., Rawley, O., Smith, O. P., & O'Donnell, J. S.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2012-04-25
- Volume
- 157
- Issue
- 6
- Pages
- 653-663
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2071507649
- Cited by
- 285
- References
- 69
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Elevated factor VIII levels and risk of venous thrombosis. https://app.cochat.ai/papers/10.1111/j.1365-2141.2012.09134.x
- The paper
- Jenkins, P. V., Rawley, O., Smith, O. P., & O'Donnell, J. S. (2012). Elevated factor VIII levels and risk of venous thrombosis. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2012.09134.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.